Surgery Websites
Transplant Surgery »  Meet the Team »  Hepatology »  Marion G. Peters, M.D.
Marion G. Peters, M.D.

Marion G. Peters, M.D.

Professor, Department of Medicine
John V. Carbone, M.D., Endowed Chair in Medicine
Chief of Hepatology Research

Contact Information

Appointments: (415) 353-2318
marion.peters@ucsf.edu
Open Popup
  • Melbourne University Medical School, Melbourne, Australia, M.B.B.S., 1972, Medicine
  • St. Vincent's Hospital Medical School, Melbourne, Australia, Medicine
  • Melbourne University, M.D., 1991, Medicine/Immunology
  • 1973-76 Resident and Registrar in Internal Medicine, St.Vincent's Hospital, Melbourne, Australia
  • 1976-77 Clinical Research Registrar to Dr. I. R. Mackay, Royal Melbourne Hospital and The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
  • 1977-78 Gastroenterology Registrar, St. Vincent's Hospital, Melbourne, Australia
  • 1978-80 Clinical Research Fellow in Hepatology to Dr. T. B. Reynolds, University of Southern California, Los Angeles, CA
  • 1980-83 Visiting Fogarty Fellow to Dr. A.S. Fauci, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Disease, NIH, Bethesda, MD
  • 1983-85 Visiting Staff Fellow to Liver Diseases Section, National Institute of Arthritis,  Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD
  • American Board of Internal Medicine, Internal Medicine
  • UCSF Liver Center
  • Member, UCSF Immunology Graduate Program
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • Liver Injury and Repair
  • Viral hepatitis and the role of the host immune response.

Dr. Marion Peters is a Professor of Medicine and holds the John V. Carbone, M.D., Endowed Chair in Medicine. She is also Chief of Hepatology Research. Dr. Peters is especially interested in the immunology of chronic liver diseases, particularly viral and autoimmune hepatitis. Her research activities include studies of transgenic mouse models of liver specific T cell responses, HIV and HCV coinfection, and alcohol and HCV infection.

Dr. Peters graduated from Melbourne University Medical School, Australia in 1972. She trained in gastroenterology, hepatology and immunology at St. Vincent's Hospital, Melbourne, University of Southern California and National Institutes of Health. She was Chief of Hepatology and medical director of Liver Transplantation at Washington University School of Medicine from 1985 to 1998.

My major interest is in viral hepatitis and the role of the host immune response. My work focuses on interactions among alcohol use, cannabis use and HIV co-infection on fibrotic outcomes of HCV infection. We are currently evaluating the  predictors of progression of liver disease in HIV and HCV coinfected women within the Women's Interagency HIV Study (WIHS): the role of alcohol, cannabis, HIV status and control as well as reproductive aging on the severity and rate of progression of liver disease.

We are also studying adherence to antiretroviral therapy in HIV/HCV co-infected women and on HCV-specific and innate immune responses in persons co-infected with HCV and HIV. I work within the AIDS Clinical Trial Group to develop clinical trials in viral hepatitis and HIV and within the Women's Interagency HIV Study (WIHS) to examine predictors of liver-related morbidity and mortality in a cohort of women with HIV/HCV infection.

 

MOST RECENT PUBLICATIONS FROM A TOTAL OF 176
Publications provided by UCSF Profiles, powered by CTSI.
  1. Bhattacharya D, Gupta A, Tierney C, Huang S, Peters MG, Chipato T, Martinson F, Mohtashemi N, Dula D, George K, Chaktoura N, Klingman K, Gnanashanmugam D, Currier JS, Fowler MG. Hepatotoxicity and Liver-Related Mortality in Women of Child-Bearing Potential Living With HIV and High CD4 Counts Initiating Efavirenz-Containing Regimens. Clin Infect Dis. 2020 Mar 12. View in PubMed
  2. Kardashian A, Peters MG, Tien PC, Price JC. The Pathogenesis of Liver Disease in People Living With Human Immunodeficiency Virus: The Emerging Role of the Microbiome. Clin Liver Dis (Hoboken). 2020 Jan; 15(1):46-51. View in PubMed
  3. Ghany MG, Morgan TR. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020 Feb; 71(2):686-721. View in PubMed
  4. Sherman KE, Peters MG, Thomas DL. HIV and the liver. Top Antivir Med. 2019 09; 27(3):101-110. View in PubMed
  5. Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Transplant Recipients. Clin Liver Dis. 2019 08; 23(3):493-509. View in PubMed
  6. View All Publications

 

Site Directory
    X